CDKN2B and atherosclerosis: Previous studies have demonstrated that overexpression of CDKN2B-AS1 hinders vascular smooth muscle cells (VSMCs) proliferation and accelerates apoptosis via inhibiting the PI3K/AKT pathway, and also that CDKN2B-AS may promote atherosclerosis by impacting thrombogenesis, and plaque stability [4,5].